Omega Protein Announces Second Quarter 2016 Financial Results

From www.prnewswire.com by Omega Protein Corporation
Omega Protein Announces Second Quarter 2016 Financial Results

Omega Protein Corporation Logo. (PRNewsFoto/Omega Protein Corporation)

HOUSTON, Aug. 3, 2016 /PRNewswire/ -- Omega Protein Corporation (NYSE:OME), a nutritional product company and a leading integrated provider of specialty oils and specialty protein products, today reported financial results for the second quarter and six months ended June 30, 2016.

Second Quarter 2016 Highlights

  • Revenues:  $112.7 million, compared to $93.2 million in the same period a year ago
  • Gross profit margin:  29.6%, compared to 27.7% in the same period a year ago
  • Net income: $5.7 million, or $14.1 million on an adjusted basis, compared to $8.8 million, or $9.6 million, on an adjusted basis, in the same period a year ago
  • Earnings per diluted share: $0.25, or $0.62 on an adjusted basis, compared to $0.40, or $0.43 on an adjusted basis, in the same period a year ago
  • Adjusted EBITDA:  $28.6 million, compared to $21.6 million in the same period a year ago

"Our second quarter consolidated financial results reflect the continued strength in our animal nutrition segment," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer.  "We are pleased with our season-to-date fish catch and higher fish oil yields.  At the same time, we are intently focused on the improvement of our human nutrition segment as we build a stronger foundation through our strategic initiatives and regain operating momentum for sustainable growth.  Going forward, we will continue to leverage our competitive advantages to drive growth in revenues and further improve operational efficiencies across both our animal and human nutrition segments."

Second Quarter 2016 Results
The Company's revenues increased 21% from $93.2 million in the same period last year to $112.7 million.  This increase was due to an increase in animal nutrition revenues of $24.7 million, partially offset by a $5.3 million decrease in human nutrition revenues. The increase in animal nutrition revenues was primarily due to increased sales volumes of 47% and 101% for the Company's fish meal and fish oil, respectively, partially offset by decreased sales prices of 9% and 20% for the Company's fish meal and fish oil, respectively.  The decrease in fish oil sales prices is a reflection of prevailing market conditions and prices when underlying sales contracts were executed, as well as a change in the product mix of higher priced refined and lower priced crude oils.  The decrease in human nutrition revenues was primarily due to lower sales of specialty oils, partially offset by increased sales of protein products.  The composition of revenues by nutritional product line for the second quarter of 2016 was 38% fish meal, 33% fish oil, 28% dietary supplements and 1% fish solubles and other. 

Second quarter of 2016 revenues increased 33% from $84.8 million in the first quarter of 2016 to $112.7 million. This increase was due to a $31.4 million increase in animal nutrition revenues, partially offset by a decrease of $3.6 million in human nutrition revenues. The increase in animal nutrition revenues was due to increased fish meal and fish oil sales volumes of 28% and 181% respectively, partially offset by decreased fish meal and fish oil sales prices of 2% and 12%, respectively. The decrease in human nutrition revenues was primarily due to decreased sales of specialty oils, partially offset by increased sales of protein products.

The Company reported gross profit of $33.4 million, or 29.6% as a percentage of revenues, for the second quarter of 2016, versus $25.8 million, or 27.7% as a percentage of revenues, in the second quarter of 2015. The increase in gross profit as a percentage of revenues was due to an improvement in the animal nutrition segment, partially offset by a decrease in the human nutrition segment. Animal nutrition gross profit as a percentage of revenues increased from 36.7% to 37.4%, due primarily to higher fish catch and production in 2015 compared to 2014, which led to a decrease in the cost per unit of sales in the 2016 period. Human nutrition gross profit as a percentage of revenues decreased from 13.7% to 9.2% due primarily to decreased gross profit as a percentage of revenues for specialty oils.   

Compared to the first quarter of 2016, second quarter gross profit increased from $24.8 million, or 29.3% as a percentage of revenues, to $33.4 million, or 29.6% as a percentage of revenues.  The increase in gross profit as a percentage of revenues was due to an increase in the proportion of revenues attributable to the animal nutrition segment.  Animal nutrition gross profit as a percentage of revenues decreased from 40.7% to 37.4% due to a higher cost per unit of sales for 2016 production.  Human nutrition gross profit as a percentage of revenues decreased from 12.6% to 9.2% primarily as a result of lower gross profit as a percentage of revenues for protein products and specialty oils, due in part to a $0.6 million protein product inventory write-down.

Selling, general and administrative expense, including research and development expense ("SG&A"), for the second quarter increased to $11.8 million compared to $10.8 million in the second quarter of 2015 and $9.6 million in the first quarter of 2016.  The increases were primarily due to professional fees for services as a result of the Company's proxy contest, as well as labor and other expenses.

The Company recorded goodwill impairment expenses in the second quarter of 2016 of $11.6 million related to the Wisconsin Specialty Protein business in the human nutrition segment.  There were no impairment charges recognized in the second quarter of 2015. 

Plant closure expenses were $1.0 million in the second quarter of 2016 compared to $0.6 million in the second quarter of 2015. The second quarter of 2016 expense is primarily due to the Company's decision to focus its omega-3 oils manufacturing operations on non-concentrated oils and dispose of its oil concentration facility.

Gain on foreign currency related to Bioriginal Food & Science ("Bioriginal") was $0.1 million for the second quarter of 2016 compared to a $0.1 million gain in the second quarter of 2015 and a $1.4 million loss in the first quarter of 2016.

Net income for the second quarter of 2016 was $5.7 million ($0.25 per diluted share) compared to $8.8 million ($0.40 per diluted share) in the same period last year and $8.4 million ($0.37 per diluted share) in the first quarter of 2016. Excluding adjustments for certain items, adjusted net income for the second quarter of 2016 would have been $14.1 million ($0.62 per diluted share), compared to $9.6 million ($0.43 per diluted share) in the same period last year and $9.1 million ($0.40 per diluted share) for the first quarter of 2016. 

Adjusted EBITDA totaled $28.6 million for the second quarter of 2016, compared to $21.6 million for the same period last year and $20.4 million for the first quarter of 2016.

Six Month 2016 Results
Revenues in the first six months of 2016 increased 20% to $197.5 million compared to $164.8 million for the six months ended June 30, 2015. The increase in revenues was due to a $38.1 million increase in animal nutrition revenues partially offset by a $5.4 million decrease in human nutrition revenues. The increase in animal nutrition revenues was primarily due to increased sales volumes of 41% and 102% for the Company's fish meal and fish oil, respectively, partially offset by decreased sales prices of 7% and 20% for the Company's fish meal and fish oil, respectively. The decrease in fish oil sales prices is mainly a reflection of prevailing market conditions and prices when underlying sales contracts were executed, as well as a change in the product mix of higher priced refined and lower priced crude oils.  The decrease in human nutrition revenues was primarily due to a decrease in sales of specialty oils and other nutraceutical ingredients, partially offset by an increase in sales of protein products.

The Company recorded gross profit of $58.2 million, or 29.5% as a percentage of revenues, for the first six months of 2016, versus gross profit of $40.6 million, or 24.7% as a percentage of revenues, for the first six months of 2015. The increase in gross profit as a percentage of revenues was due to an improvement in the animal nutrition segment from 33.5% to 38.7%, and an increase in the proportion of revenues attributable to the animal nutrition segment, partially offset by a reduction in human nutrition gross profit as a percentage of revenues from 13.0% to 11.0%.

Net income for the six months ended June 30, 2016 was $14.0 million ($0.62 per diluted share) compared to $10.5 million ($0.47 per diluted share) for the same period last year. Excluding adjustments for certain items, net income for the six months ended June 30, 2016 would have been $23.2 million ($1.03 per diluted share) compared to $12.2 million ($0.55 per diluted share).

Adjusted EBITDA totaled $49.1 million for six months ended June 30, 2016, an increase from $32.0 million for the same period last year.

Balance Sheet
Total debt decreased $18.1 million from $24.1 million on December 31, 2015 to $6.0 million on June 30, 2016.  Stockholders' equity increased $18.5 million to $313.7 million as of June 30, 2016 compared to $295.2 million as of December 31, 2015.

Conference Call Information
Omega Protein will host a conference call on its second quarter and six month financial results at 8:30 a.m., Eastern Time, on Thursday, August 4, 2016. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.

A webcast replay of the conference call and the prepared remarks will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic playback will be available from 11:30 a.m. ET, August 4, 2016, through August 18, 2016. Participants can dial (877) 870-5176 in North America, and international listeners may dial (858) 384-5517. The password is 13640505.

About Omega Protein Corporation
Omega Protein Corporation (NYSE: OME) is a century old nutritional product company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of foods, dietary supplements and animal feeds. Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined specialty oils, specialty protein products and nutraceuticals.

The Company operates eight manufacturing facilities located in the United States, Canada and Europe. The Company also operates more than 30 vessels to harvest menhaden, a fish abundantly found in the Atlantic Ocean and Gulf of Mexico.

For More Information
Visit Omega Protein at www.omegaprotein.com, follow us on Twitter at https://twitter.com/omegaprotein, or find us on LinkedIn at https://www.linkedin.com/company/omega-protein-inc-.

Forward-Looking Statements
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products or increase the cost of compliance; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company's financial results; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company's deferral of inventory sales based on worldwide prices for competing products; (6) the Company's ability to realize the anticipated benefits from its acquisitions in the human nutrition business, and specifically, to integrate successfully its acquisitions in the human nutrition segment; (7) the Company's expectations regarding Bioriginal, its future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) increase in the price and shortage of key raw materials that could adversely affect Bioriginal's businesses; (9) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions; (10) the resolution of the U.S. Attorney's criminal investigation with respect to the Company's waste water discharge practices and the resulting impact on the Company's 2013 plea agreement and terms of probation and the Company's business, reputation, results of operation and financial condition; (11) the impact of the Company's decision to exit the concentrated oils manufacturing business and dispose of its oil concentration facility on the Company's business, financial conditions and results of operations, including the amount of losses that may be incurred in connection herewith; and (12) the ability of the Company to purchase shares of its common stock under the share repurchase program due to changes in stock price or other conditions.  Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.  Except as required by law, the Company expressly disclaims any intention or obligation to revise or update any forward-looking information whether as a result of new information, future events or otherwise.

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

June 30,
2016

December 31,
2015

ASSETS

 Current assets:

          Cash and cash equivalents

$

6,404

$

661

          Receivables, net

55,215

40,489

          Inventories

106,989

119,994

          Deferred tax asset, net

2,496

3,422

          Prepaid expenses and other current assets

6,096

4,496

                Total current assets

177,200

169,062

Property, plant and equipment, net

179,862

176,089

Goodwill

26,597

38,127

Other intangible assets, net

19,162

20,107

Other assets, net

5,665

3,818

                Total assets

$

408,486

$

407,203

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

         Current maturities of long-term debt

$

1,807

$

1,214

         Accounts payable

10,786

15,876

         Accrued liabilities

41,752

33,254

              Total current liabilities

54,345

50,344

Long-term debt, net of current maturities

4,201

22,882

Deferred tax liability, net

26,109

27,844

Pension liabilities, net

5,845

6,048

Other long-term liabilities

4,316

4,915

                Total liabilities

94,816

112,033

Commitments and contingencies

Stockholders' equity:

        Preferred stock, $0.01 par value; 10,000,000 authorized shares; none issued

        Common Stock, $0.01 par value; 80,000,000 authorized shares; 22,463,801 and 22,371,179 shares issued and 22,297,073 and 22,221,027 shares outstanding at June 30, 2016 and December 31, 2015, respectively

221

220

        Capital in excess of par value

152,814

151,250

        Retained earnings

173,286

159,243

        Treasury stock, at cost  – 166,728 and 150,152 shares at June 30, 2016 and December 31, 2015, respectively

(2,863)

(2,505)

        Accumulated other comprehensive loss

(9,788)

(13,038)

                Total stockholders' equity

313,670

295,170

                    Total liabilities and stockholders' equity

$

408,486

$

407,203

 

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share amounts)

Three Months Ended

Six Months Ended

June 30,

June 30,

2016

2015

2016

2015

Revenues

$

112,650

$

93,176

$

197,493

$

164,799

Cost of sales

79,252

67,345

139,276

124,173

Gross profit

33,398

25,831

58,217

40,626

Selling, general, and administrative expense

11,106

9,997

20,039

19,413

Research and development expense

713

770

1,349

1,544

Impairment of goodwill and other intangible assets

11,614

11,614

Loss related to plant closure

1,023

649

1,665

1,287

(Gain) loss on disposal of assets

(31)

27

(66)

334

Operating income

8,973

14,388

23,616

18,048

Interest expense

(134)

(465)

(279)

(823)

Gain (loss) on foreign currency

73

83

(1,358)

(462)

Other income (expense), net

116

(94)

37

(204)

Income before income taxes

9,028

13,912

22,016

16,559

Provision for income taxes

3,365

5,108

7,973

6,086

Net income

5,663

8,804

14,043

10,473

Other comprehensive income (loss):

Foreign currency translation adjustment net of tax (expense) benefit of ($194), ($180), ($584) and $706, respectively

360

334

1,085

(1,311)

Energy swap adjustment, net of tax expense of $863, $354, $927 and $319, respectively

1,603

657

1,721

593

Pension benefits adjustment, net of tax expense of $120, $105, $239 and $210, respectively

222

195

444

390

Comprehensive income

$

7,848

$

9,990

$

17,293

$

10,145

Basic earnings per share

$

0.25

$

0.41

$

0.63

$

0.48

Weighted average common shares outstanding

21,885

21,111

21,873

21,059

Diluted earnings per share

$

0.25

$

0.40

$

0.62

$

0.47

Weighted average common shares and potential common share equivalents outstanding

22,180

21,573

22,174

21,522

 

OMEGA PROTEIN CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

Six Months Ended

June 30,

2016

2015

Cash flows from operating activities:

       Net income

$

14,043

$

10,473

       Adjustments to reconcile net income to net cash provided by operating activities:

        Depreciation and amortization

12,599

11,911

        Loss related to plant closures

1,986

        Loss (gain) on disposal of assets

(66)

334

        Impairment of goodwill and other intangible assets

11,614

        Provisions for losses on receivables

29

24

        Share based compensation

1,071

999

        Deferred income taxes

(1,747)

(16)

        Unrealized loss on foreign currency fluctuations, net

1,358

462

        Changes in assets and liabilities:

                 Receivables

(14,930)

(20,710)

                 Inventories

13,091

(4,625)

                 Prepaid expenses and other current assets

(1,596)

(2,154)

                 Other assets

(2,117)

(732)

                 Accounts payable

(5,271)

(8,536)

                 Accrued liabilities

11,989

7,326

                 Pension liability, net

241

(263)

                 Other long term liabilities

(390)

1,245

                         Net cash provided by (used in) operating activities

41,904

(4,262)

Cash flows from investing activities:

        Capital expenditures

(18,272)

(21,030)

        Proceeds from disposition of assets

85

36

                         Net cash used in investing activities

(18,187)

(20,994)

Cash flows from financing activities:

        Principal payments of long-term debt

(24,500)

(3,793)

        Proceeds from long-term debt

6,392

27,827

        Treasury stock repurchase

(358)

(158)

        Proceeds from equity compensation transactions

283

846

        Excess tax benefit of equity compensation transactions

211

151

                         Net cash (used in) provided by financing activities

(17,972)

24,873

Net increase (decrease) in cash and cash equivalents

5,745

(383)

Translation effect on cash

(2)

Cash and cash equivalents at beginning of year

661

1,430

Cash and cash equivalents at end of period

$

6,404

$

1,047

 

The tables below present information about reported segments for the three months ended June 30, 2016 and 2015 (in thousands): 

2016

Animal
Nutrition

Human
Nutrition

Unallocated

Total

Revenue (1)

$  81,602

$    31,048

  $          ―

$  112,650

Cost of sales

51,074

28,178

 ―

79,252

Gross profit

30,528

2,870

33,398

Selling, general and administrative expenses (including research and development)

662

4,473

6,684

11,819

Impairment of goodwill and other intangible assets

11,614

11,614

(Gain) loss related to plant closures

(350)

1,373

1,023

Other (gains) and losses

(31)

(31)

Operating income

$  30,247

$  (14,590)

$   (6,684)

$      8,973

Depreciation and amortization

$     4,740

$      1,453

$        190

$      6,383

Identifiable assets

$ 256,755

$  140,937

$   10,794

$  408,486

Capital expenditures

$     7,442

$         429

$        697

$      8,568

2015

Animal
Nutrition

Human
Nutrition

Unallocated

Total

Revenue (2)

$   56,871

$   36,305

  $         ―

$    93,176

Cost of sales

36,007

31,338

67,345

Gross profit

20,864

4,967

25,831

Selling, general and administrative expense (including research and development)

536

5,087

5,144

10,767

Loss related to plant closure

649

649

Other (gains) and losses

27

27

Operating income

$    19,652

$       (120)

$    (5,144)

$    14,388

Depreciation and amortization

$      4,376

$     1,528

$         129

$      6,033

Identifiable assets

$  243,720

$ 168,570

$      1,874

$  414,164

Capital expenditures

$      8,376

$     1,382

$         712

$    10,470

 

(1)  Excludes revenue from internal customers of $0.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

(2)  Excludes revenue from internal customers of $0.6 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

The tables below present information about reported segments for the six months ended June 30, 2016 and 2015 (in thousands):

2016

Animal
Nutrition

Human
Nutrition

Unallocated

Total

Revenue (3)

$ 131,797

$    65,696

  $          ―

$   197,493

Cost of sales

80,823

58,453

139,276

Gross profit

50,974

7,243

58,217

Selling, general and administrative expenses (including research and development)

1,148

8,609

11,631

21,388

Impairment of goodwill and other intangible assets

11,614

 ―

11,614

(Gain) loss related to plant closures

(313)

1,978

1,665

Other (gains) and losses

(66)

(66)

Operating income

$   50,205

$  (14,958)

$  (11,631)

$   23,616

Depreciation and amortization

$     9,410

$      2,807

$         382

$   12,599

Identifiable assets

$ 256,755

$  140,937

$    10,794

$ 408,486

Capital expenditures

$   15,904

$      1,504

$         864

$   18,272

2015

Animal
Nutrition

Human
Nutrition

Unallocated

Total

Revenue (4)

$   93,700

$   71,099

  $         ―

$  164,799

Cost of sales

62,290

61,883

124,173

Gross profit

31,410

9,216

40,626

Selling, general and administrative expense (including research and development)

1,093

10,116

9,748

20,957

Loss related to plant closure

1,287

1,287

Other (gains) and losses

334

334

Operating income (loss)

$   28,696

$      (900)

$    (9,748)

$    18,048

Depreciation and amortization

$     8,649

$     3,027

$         235

$    11,911

Identifiable assets

$ 243,720

$ 168,570

$      1,874

$  414,164

Capital expenditures

$   17,489

$     2,333

$      1,208

$   21,030

 

(3) Excludes revenue from internal customers of $0.5 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

(4) Excludes revenue from internal customers of $1.0 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

 

Adjusted EBITDA to Net Income Reconciliation
The following table (in thousands) provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2016, March 31, 2016 and June 30, 2015 and the six months ended June 30, 2016 and 2015:

                                                                                                                                                  

Three Months Ended

June 30,
2016

March 31,
2016

June 30,
2015

Net Income

$

5,663

$

8,380

$

8,804

Reconciling items:

   Interest expense

75

86

434

   Income tax provision

3,365

4,608

5,108

   Depreciation and amortization (1)

6,383

6,216

6,033

   Impairment of goodwill and other intangible assets (2)

11,614

                 ―

                ―

   Loss related to plant closure (1)

1,023

642

649

   Acquisition post-closing consideration (2)

556

546

577

   (Gain) loss on disposal of assets (1)

(31)

(35)

27

Adjusted EBITDA

$

28,648

$

20,443

$

21,632

                                                                                                                                       

Six Months Ended

June 30,
2016

June 30,
2015

Net Income

$

14,043

$

10,473

Reconciling items:

   Interest expense

161

766

   Income tax provision

7,973

6,086

   Depreciation and amortization (1)

12,599

11,911

   Impairment of goodwill and other intangible assets (2)

11,614

 ―

   Loss related to plant closure (1)

1,665

1,287

   Acquisition post-closing consideration (2)

1,102

1,151

   (Gain) loss on disposal of assets (1)

(66)

334

Adjusted EBITDA

$

49,091

$

32,008

(1) See segment disclosures for allocation among segments.

(2) Relates to human nutrition segment.

 

Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, impairment of goodwill and other intangible assets, loss related to plant closures, acquisition post-closing consideration and (gain) loss on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation
The following table (in thousands, except per share amounts) provides a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2016, March 31, 2016 and June 30, 2015 and the six months ended June 30, 2016 and 2015:

                                                                                                                                                  

Three Months Ended

June 30,
2016

March 31,
2016

June 30,
2015

Net Income

$

5,663

$

8,380

$

8,804

Reconciling items:

     Income tax provision prior to adjustments

3,365

4,608

5,108

     Impairment of goodwill and other intangible assets

11,614

     Loss related to plant closure

1,023

642

649

     Acquisition post-closing consideration

556

546

577

     (Gain) loss on disposal of assets

(31)

(35)

27

Adjusted income before income taxes

22,190

14,141

15,165

     Provision for income taxes after adjustments

8,138

5,020

5,568

Adjusted net income

$

14,052

$

9,121

$

9,597

Adjusted diluted earnings per share

$

0.62

$

0.40

$

0.43

                                                                                                                                       

Six Months Ended

June 30,
2016

June 30,
2015

Net Income

$

14,043

$

10,473

Reconciling items:

     Income tax provision prior to adjustments

7,973

6,086

     Impairment of goodwill and other intangible assets

11,614

     Loss related to plant closure

1,665

1,287

     Acquisition post-closing consideration

1,102

1,151

     (Gain) loss on disposal of assets

(66)

334

Adjusted income before income taxes

36,331

19,331

     Provision for income taxes after adjustments

13,158

7,107

Adjusted net income

$

23,173

$

12,224

Adjusted diluted earnings per share

$

1.03

$

0.55

Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without impairment of goodwill and other intangible assets, loss related to plant closures, acquisition post-closing consideration and (gain) loss on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis.  Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share have been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States.

Human Nutrition Segment Financial Information Reconciliation
The following table (in thousands) provides a breakdown of the total Human Nutrition Segment revenue, cost of sales and gross profit among concentrated menhaden oil products and tolling, dairy protein products and other products for the three and six months ended June 30, 2016.

Three Months Ended

Total
Human
Nutrition
Segment

Concentrated
Menhaden
Oil Products
and Tolling

Segment Less
Concentrated
Menhaden

Oil Products
and Tolling

Dairy
Protein
Products

Other Products
from Human
Nutrition
Segment

Revenue

$  31,048

$     439

$   30,609

$    5,216

$   25,393

Cost of sales

28,178

829

27,349

5,503

21,846

Gross profit (loss)

$    2,870

$   (390)

$     3,260

$     (287)

$     3,547

Gross profit margin

9.2%

(88.8%)

10.7%

(5.5%)

14.0%

Six Months Ended

Total
Human
Nutrition
Segment

Concentrated
Menhaden
Oil Products
and Tolling

Segment Less
Concentrated
Menhaden
Oil Products
and Tolling

Dairy
Protein
Products

Other Products
from Human
Nutrition
Segment

Revenue

$  65,696

$     1,292

$   64,404

$    9,593

$   54,811

Cost of sales

58,453

2,578

55,875

9,430

46,445

Gross profit (loss)

$    7,243

$   (1,286)

$     8,529

$       163

$     8,366

Gross profit margin

11.0%

(99.5%)

13.2%

1.7%

15.3%

 

The Company has provided a breakdown of total Human Nutrition Segment revenue, cost of sales and gross profit among concentrated menhaden oil products, dairy protein products and other human nutrition products because it believes such a breakdown will provide investors with additional useful detail on the performance of the Human Nutrition Segment. 

Logo - http://photos.prnewswire.com/prnh/20120717/NE41641LOGO

 

SOURCE Omega Protein Corporation

Continue reading at PR Newswire Cook